OBJECTIVES: The integrase strand inhibitor dolutegravir (DTG) combined with tenofovir and lamivudine (TLD) is a single tablet regimen recommended for 1st, 2nd and 3rd-line public health antiretroviral therapy (ART). We determined drug resistance mutations (DRMs) and evaluated the predictive efficacy of a TLD containing regimen for viremic adolescents and young adults in Harare, Zimbabwe. METHODS: We sequenced plasma viral RNA from HIV-1-infected adolescents and young adults on 1st and 2nd-line ART with confirmed virologic failure (viral load >1000 copies/ml) and calculated total genotypic susceptibility scores to current 2nd, 3rd line and DTG regimens. RESULTS: A total of 160 participants were genotyped; 112 (70%) on 1st line and 48 (30%) on 2nd line, median (interquartile range) age 18 (15-19) and duration of ART (interquartile range) was 6 (4-8) years. Major DRMs were present in 94 and 67% of 1st and 2nd-line failures, respectively (P < 0.001). Dual class resistance to nucleotide reverse transcriptase inhibitors and nonnucleotide reverse transcriptase inhibitors was detected in 96 (60%) of 1st-line failures; protease inhibitor DRMs were detected in a minority (10%) of 2nd-line failures. A total genotypic susceptibility score of 2 or less may risk protease inhibitor or DTG monotherapy in 11 and 42% of 1st-line failures switching to 2nd-line protease inhibitor and TLD respectively. CONCLUSION: Among adolescents and young adults, current protease inhibitor-based 2nd-line therapies are poorly tolerated, more expensive and adherence is poor. In 1st-line failure, implementation of TLD for many adolescents and young adults on long-term ART may require additional active drug(s). Drug resistance surveillance and susceptibility scores may inform strategies for the implementation of TLD.
OBJECTIVES: The integrase strand inhibitor dolutegravir (DTG) combined with tenofovir and lamivudine (TLD) is a single tablet regimen recommended for 1st, 2nd and 3rd-line public health antiretroviral therapy (ART). We determined drug resistance mutations (DRMs) and evaluated the predictive efficacy of a TLD containing regimen for viremic adolescents and young adults in Harare, Zimbabwe. METHODS: We sequenced plasma viral RNA from HIV-1-infected adolescents and young adults on 1st and 2nd-line ART with confirmed virologic failure (viral load >1000 copies/ml) and calculated total genotypic susceptibility scores to current 2nd, 3rd line and DTG regimens. RESULTS: A total of 160 participants were genotyped; 112 (70%) on 1st line and 48 (30%) on 2nd line, median (interquartile range) age 18 (15-19) and duration of ART (interquartile range) was 6 (4-8) years. Major DRMs were present in 94 and 67% of 1st and 2nd-line failures, respectively (P < 0.001). Dual class resistance to nucleotide reverse transcriptase inhibitors and nonnucleotide reverse transcriptase inhibitors was detected in 96 (60%) of 1st-line failures; protease inhibitor DRMs were detected in a minority (10%) of 2nd-line failures. A total genotypic susceptibility score of 2 or less may risk protease inhibitor or DTG monotherapy in 11 and 42% of 1st-line failures switching to 2nd-line protease inhibitor and TLD respectively. CONCLUSION: Among adolescents and young adults, current protease inhibitor-based 2nd-line therapies are poorly tolerated, more expensive and adherence is poor. In 1st-line failure, implementation of TLD for many adolescents and young adults on long-term ART may require additional active drug(s). Drug resistance surveillance and susceptibility scores may inform strategies for the implementation of TLD.
Authors: Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme Journal: Bioinformatics Date: 2005-08-02 Impact factor: 6.937
Authors: Kim C E Sigaloff; Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Prudence Ive; Mariette E Botes; Kishor Mandaliya; Maureen Wellington; Akin Osibogun; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Kathryn Anastos; Stephen J Gange; Howard Minkoff; Mary Young; Joel Milam; Mardge H Cohen; Gerald B Sharp; Yong Huang; Ruth M Greenblatt Journal: Clin Infect Dis Date: 2011-05 Impact factor: 9.079
Authors: Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes Journal: Clin Infect Dis Date: 2008-05-15 Impact factor: 9.079
Authors: Mina C Hosseinipour; Joep J G van Oosterhout; Ralf Weigel; Sam Phiri; Debbie Kamwendo; Neil Parkin; Susan A Fiscus; Julie A E Nelson; Joseph J Eron; Johnstone Kumwenda Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Soo-Yon Rhee; Michael Boehm; Olga Tarasova; Giulia Di Teodoro; Ana B Abecasis; Anders Sönnerborg; Alexander J Bailey; Dmitry Kireev; Maurizio Zazzi; Robert W Shafer Journal: Pathogens Date: 2022-05-05